Cargando…
ACE2 trials suggest remodeling, not dilation, as primary therapeutic effect
Autor principal: | West, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053010/ https://www.ncbi.nlm.nih.gov/pubmed/35506063 http://dx.doi.org/10.1002/pul2.12022 |
Ejemplares similares
-
Suggestive Therapeutics
Publicado: (1889) -
Recombinant human ACE2: acing out angiotensin II in ARDS therapy
por: Zhang, Haibo, et al.
Publicado: (2017) -
rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling
por: Rathinasabapathy, Anandharajan, et al.
Publicado: (2018) -
ACE2: The Only Thing That Matters?
por: Sanchez-David, Raul Y., et al.
Publicado: (2020) -
Myocardial remodelling and recovery in dilated cardiomyopathy
por: Tayal, Upasana, et al.
Publicado: (2017)